Study Finds Psoriasis Drug Significantly Effective in Treating Crohn’s Disease

Researchers at University of California San Diego School of Medicine have shown that ustekinumab, a human antibody used to treat arthritis, significantly induces response and remission in patients with moderate to severe Crohn’s disease. Results of the clinical trial will appear in the November 16 issue of the New England Journal of Medicine.

“A high percentage of the patients in the study who had not responded to conventional therapies were in clinical remission after only a single dose of intravenous ustekinumab,” said William J. Sandborn, MD, professor of medicine at UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health. … Read the Full Story from the UC San Diego Newsroom


Dr. William Sandborn

William J. Sandborn, MD

William A. Sandborn, MD, is chief of the Division of Gastroenterology in the Department of Medicine.

Study Finds Potential New Drug Therapy for Crohn’s Disease

Ustekinumab Induces, Sustains Clinical Response in Patients

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results in decreasing the debilitating effects of Crohn’s Disease, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the October 18, 2012 issue of the New England Journal of MedicineRead the full story from the UCSD Newsroom


Dr. William J. SandbornThe principal investigator of the study is Dr. William J. Sandborn, professor of medicine and chief of the Division of Gastroenterology at UCSD.  |  Read his academic profile  |  Read his clinical profile

Read the report of the study in the New England Journal of Medicine (full text UCSD only)

Citation of study report:  Sandborn WJ, Gasink C, Gao L-L, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P,  Ghosh S, de Villiers WJS, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG for the CERTIFI Study Group. N Engl J Med 2012; 367:1519-1528 October 18, 2012 DOI: 10.1056/NEJMoa1203572

Protein May Be Key to Psoriasis and Wound Care

Psoriasis is an autoimmune disorder in which skin cells proliferate out of control. For some hard-to-heal wounds, the problem is just the opposite: Restorative skin cells don’t grow well or fast enough. In a paper published in the June 21, 2012 issue of Immunity, researchers at the University of California, San Diego School of Medicine describe a molecule that may lead to new treatments for both problems. … Read the full story from the UCSD Newsroom


Dr. Richard GalloThe principal investigator of this collaborative study is Richard L. Gallo, MD, PhD, professor of medicine and chief of the Division of Dermatology at UC San Diego.

The other Department of Medicine co-authors are Tissa Hata, MD, professor of medicine, Clinical Service Chief for Dermatology at the Perlman Ambulatory Care Center and Director of the UCSD Dermatology Clinical Trials Unit; Beda Mühleisen, MD; and Paul Kotol.

More information:

  • Read the article summary in Immunity.
  • Citation: Yuping Lai, Dongqing Li, Changwei Li, Beda Muehleisen, Katherine A. Radek, Hyun Jeong Park, Ziwei Jiang, Zhiheng Li, Hu Lei, Yanchun Quan, Tian Zhang, Yelin Wu, Paul Kotol, Shin Morizane, Tissa R. Hata, Keiji Iwatsuki, Ce Tang, Richard L. Gallo, The Antimicrobial Protein REG3A Regulates Keratinocyte Proliferation and Differentiation after Skin Injury, Immunity, Available online 21 June 2012, ISSN 1074-7613, 10.1016/j.immuni.2012.04.010.
  • Dr. Gallo’s laboratory website